Revolutionizing Interventional Endoscopy One Centimeter at a Time.
Developing a suite of advanced gastrointestinal therapies to meet the rising demand for interventional procedures across the GI tract, starting with distraction enterogenesis for Short Bowel Syndrome (SBS) and expanding into cancer resection, bleeding control, and stent anchoring.
Introducing the Eclipse XL1.
The Eclipse XL1 is the first device designed to regenerate healthy intestinal tissue using your body’s own biology. Our approach may offer patients a chance to grow their intestine, without transplant or dependence on parenteral nutrition.
More Than a Single Device. A New Frontier in GI Care.
The Eclipse XL1 is the first step in our broader mission: to transform how the world treats intestinal failure. While our lead application targets pediatric Short Bowel Syndrome (SBS), our regenerative platform has implications for a wide range of gastrointestinal conditions including adult short gut, stoma reversal, gastric stenting, and ulcer repair.
We’re building a new standard in GI intervention, backed by science, surgical insight, and bold vision.
The First Step: Solving Short Bowel Syndrome
Why Short Bowel Syndrome Needs a New Solution.
SBS patients face a lifetime of complications – malnutrition, constant medical care, and limited quality of life. Current treatments are limited and invasive, often requiring long-term parenteral nutrition or transplant. We’re building a future where regeneration, not replacement, is the path forward.
This is our proving ground and the first of many high-need areas where our technology can drive change.
Total Parenteral Nutrition (TPN)
- Lifelong Intravenous (IV) feeding and nutritional support
- Frequent hospitalizations for venous catheter-associated complications (infections, displacement, etc.)
- Toxicity often leading to end-stage liver disease
Drug Therapy (Teduglutide Injections)
- Daily injections
- Minimal improvement in absorption (max 20%)
- TPN/IV nutrition still required
Surgery and Intestinal Transplantation
- May not increase nutrient absorption
- May require lifelong immunosuppression drugs
- High risk of infection, rejection, death
Driven by Science. United by Purpose.
We’re a team of physicians, engineers, and entrepreneurs committed to changing the future of gastrointestinal care. Our mission: harness the body’s healing potential to restore what was lost.
Proudly Partnered
Our commitment to patient-centered innovation is driven by our partnerships with some of the leading healthcare organizations in the world. Eclipse Regenesis is proudly partnered with Boston Children’s Hospital, Cincinnati Children’s, UCLA Health, and Stanford Medicine. Together with our partners, we continue to pioneer the next generation of treatment for patients with Short Bowel Syndrome (SBS).
Join Us in Redefining the Future of GI Care.
Whether you’re a clinician, investor, or family seeking better options, we’re building a future where intestinal healing begins from within.